
Sign up to save your podcasts
Or


Highlighting the importance of BCMA-CAR T therapy for patients with relapsed refractory multiple myeloma and discusses future avenues of clinical investigation.
Read the related article "T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma" on JCO.org
By American Society of Clinical Oncology (ASCO)3.8
3939 ratings
Highlighting the importance of BCMA-CAR T therapy for patients with relapsed refractory multiple myeloma and discusses future avenues of clinical investigation.
Read the related article "T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma" on JCO.org

14,364 Listeners

137 Listeners

320 Listeners

498 Listeners

58 Listeners

112,758 Listeners

44 Listeners

32 Listeners

195 Listeners

90 Listeners

364 Listeners

253 Listeners

189 Listeners

41 Listeners

613 Listeners